The onset of the new year brings with it the first major event in 2025: The launch of the first ustekinumab biosimilar (reference product, Stelara). However, several important developments will be worth watching over the next 12 months. Here are some of the most notable, including several ustekinumab biosimilar launches: Ustekinumab: The Second Pharmacy Benefit–Covered … Continue reading What’s Next for Biosimilars in 2025?